title: Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
abstract: BACKGROUND
  Women with ovarian cancer treated with chemotherapeutic platinum agents frequently develop hypersensitivity reactions (HSRs). How best to risk-stratify patients for desensitization is uncertain.
  
  
  OBJECTIVE
  To evaluate skin test (ST) reactivity to carboplatin in patients with recent and remote histories of carboplatin HSR and to review the relationship between skin test reactivity and tolerance of subsequent carboplatin desensitization.
  
  
  METHODS
  Thirty-eight women with carboplatin HSR were evaluated by ST to carboplatin. Thirty women subsequently underwent 106 desensitizations to carboplatin.
  
  
  RESULTS
  Carboplatin ST was positive in 25 of 38 patients (66%). Of patients with recent HSR (<3 months), 20 of 24 (83%) tested positive, whereas 5 of 14 (36%) with remote HSR (>9 months) tested positive (P < .01). Nineteen carboplatin ST+ and 11 ST- patients underwent desensitization to carboplatin. Seven ST+ patients (37%) had mild HSR during desensitization but completed the desensitization with additional treatment or protocol modification. ST- patients with a recent history of HSR (n = 3) tolerated a rapid protocol without HSR and remained ST- with repeated testing. Six of 8 ST- patients (75%) with remote HSR reacted during desensitization. The HSRs were more severe and often associated with an elevated tryptase level. Five of 7 patients retested became ST+ before the second desensitization. Carboplatin desensitization was successfully completed in 105 of 106 (99%) treatment courses.
  
  
  CONCLUSIONS
  The timing of carboplatin ST in relation to initial HSR is vital for risk stratification and subsequent desensitization. Initial ST- patients with a remote history of HSR are at high risk for conversion to ST+ and can develop more severe HSR.
authors.affiliation: Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA 02114, USA. phesterberg@partners.org
authors.forename: Paul E
authors.initials: PE
authors.lastname: Hesterberg
authors.forename: Aleena
authors.initials: A
authors.lastname: Banerji
authors.forename: Eyal
authors.initials: E
authors.lastname: Oren
authors.forename: Richard T
authors.initials: RT
authors.lastname: Penson
authors.forename: Carolyn N
authors.initials: CN
authors.lastname: Krasner
authors.forename: Michael V
authors.initials: MV
authors.lastname: Seiden
authors.forename: Johnson T
authors.initials: JT
authors.lastname: Wong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000276:immunology* / Q000627:therapeutic use; D016190:Carboplatin / Q000276:immunology* / Q000627:therapeutic use; D003888:Desensitization, Immunologic; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000209:etiology / Q000628:therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D012306:Risk; D012882:Skin Tests
chemical_list: D000970:Antineoplastic Agents; D016190:Carboplatin